Conference Call with Gland Pharma Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Gland Pharma announced Q2FY26 results Consolidated Financial Highlights: Quarterly revenue increased by 6% year-on-year; Half yearly revenues increased by 7% Quarterly R&D; investments increase to Rs 614 million against Rs 460 million in previous quarter Quarterly EBITDA increased by 6% year-on-year; Half yearly EBITDA increased by 21% Quarterly EBITDA margin stood at 21%; Half yearly EBITDA margin was at 23% Quarterly adj. EBITDA increased by 13% year-on-year; Half yearly adj. EBITDA increased by 26% Quarterly adj. EBITDA margin increased by 150 bps year-on-year; Half yearly adj. EBITDA margin increased by 370 bps Quarterly PAT increased by 12% year-on-year; Half yearly PAT increased by 30% Quarterly PAT margin increased by 70 bps year-on-year; Half yearly PAT margin increased by ~240 bps Srinivas Sadu, Executive Chairman of Gland Pharma, stated, “Gland Pharma delivered a strong first half of FY26, with Revenue growth of 7% and PAT up by 30% YoY. We expect stronger momentum in the second half, driven by new launches and Cenexi’s recovery. Our investments in global CDMO expansion, capacity enhancement in high end modalities and complex injectables pipeline continue to strengthen our foundation and support sustainable growth and long-term value for all stakeholders.” Shyamakant Giri, Chief Executive Officer of Gland Pharma, said, “For the quarter, Gland Pharma’s core business maintained its profitable growth trajectory with strong margin expansion. Encouragingly for consolidated business, we saw year-over-year improvement during the Q2FY26 with USA growing by 10% and Europe by 16%, supported by a 21% top-line increase in Cenexi. With the current momentum, we anticipate a robust growth in the upcoming quarters.” Result PDF